Semalutide, glucagon kamar peptide (GLP-1) agonist mai karɓa, an yarda da shi don kula da nau'in ciwon sukari na 2. Novo Nordisk ne ya haɓaka Somaglutide a cikin 2012 a matsayin madadin dogon lokaci zuwa Liraglutide. Idan aka kwatanta da Liraglutide da sauran magungunan ciwon sukari, ɗayan fa'idodin Somaglutide shine yana da tsawon lokacin aiki, don haka allura sau ɗaya a mako ya isa. A cikin Disamba 2017, Hukumar Abinci da Magunguna ta Amurka (FDA) ta amince da nau'in allura na somalutide. Wani gwaji na asibiti na kashi na biyu da ya gabata ya gano cewa Somaglutide ya rage nauyin nau'in masu ciwon sukari na 2 da masu kiba, kuma an yi la'akari da asarar nauyi saboda rage yawan kuzarin da ke haifar da raguwar ci.